Roundtable: Quality and Polyfunctionality in Cell Therapy Development can Broaden Therapeutic Options

Sit in with industry leaders to learn why there is a need to define best practices and improve quality management in Immunotherapy. This expert panel discussion was featured in the GEN Supplement: Immunotherapy Pipeline.

Your data is in safe hands: we'll never sell it to third parties and you may always unsubscribe. Privacy Policy.

Expert Panel Roundtable Discussion on Quality and Polyfunctionality in Cell Therapy Development Can Broaden Therapeutic Options

What influences the therapy’s results? Possibilities include the distinctive characteristics of the individual patient’s disease, the quality of the T cells taken from the patient and used to manufacture the product, the quality of the assays used to predict individual efficacy and toxicity responses, and the manufacturing process. GEN talked to five leading researchers in the field to get their input on the status of the field, the outstanding challenges, and the tools and techniques needed to help complete the circle of understanding to and advance the field.

In this E-Book we:
  • Differences in development of cell therapies vs traditional antibody therapeutics
  • Gap in the current standard methods of evaluating the quality, potency, and durability of cell therapy CAR T-cell products
  • Opportunity for future cell therapy advancements